We aim (a) to test the ability of circulating biomarkers of fibrosis (Gal-3) and adiposity (FABP4 and leptin) to predict the presence of LVA in the EAM and (b) to assess their role in the prediction of AF recurrence after PVI. This evidence concerns the gene LGALS3 and atrial fibrillation.